BRIEF-Merck To Acquire Cidara Therapeutics, Diversifying Its Portfolio To Include Late-Phase Antiviral Agent
Reuters
Nov 14
BRIEF-Merck To Acquire Cidara Therapeutics, Diversifying Its Portfolio To Include Late-Phase Antiviral Agent
Nov 14 (Reuters) - Merck & Co Inc MRK.N:
MERCK TO ACQUIRE CIDARA THERAPEUTICS, INC., DIVERSIFYING ITS PORTFOLIO TO INCLUDE LATE-PHASE ANTIVIRAL AGENT
MERCK & CO INC - TO BUY CIDARA FOR $9.2 BILLION
MERCK & CO INC PROPOSED DEAL FOR $221.50 PER SHARE IN CASH
MERCK & CO INC: UNDER TERMS OF MERGER AGREEMENT, MERCK, THROUGH A UNIT, WILL ACQUIRE ALL OF OUTSTANDING SHARES OF CIDARA
Source text: ID:nBw1hzDwPa
Further company coverage: MRK.N
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.